背景介绍:
药物性肝损伤(druginducedliverinjury,DILI)可分为固有型与特异质两类,是导致新药撤市、急性肝衰竭的主要诱因。布洛芬作为常用非甾体抗炎药,常规治疗剂量肝毒性较低,大剂量或长期暴露可诱发肝损伤,属于固有型DILI模型。酒精共暴露可显著放大其肝毒性,以氧化应激为核心机制,伴随活性氧蓄积、抗氧化系统失衡、凋亡与炎症激活。动物实验存在明显性别差异,雄性动物肝损伤表型更显著,该模型可用于非甾体抗炎药肝毒性及保肝药物评价。[1-2]
图1. 布洛芬处理后雌雄小鼠肝脏中糖酵解与脂肪酸通路相关酶的水平及表达变化[1]
布洛芬诱导动物肝损伤模型参考:[2-5]
动物信息 | 给药方式 | 给药方案 |
C57BL/6J小鼠 | 饮水 | 100mg/kg/天,连续7天 |
8-10周龄雄性Wistar大鼠 | 灌胃 | 400mg/kg/天,连续5天 |
8-10周龄雄性Wistar大鼠 | 灌胃 | 400mg/kg/天,连续4周 |
200-250g雄性Wistar大鼠 | 灌胃 | 15mg/kg/天,连续4周 |
200g雄性Wistar大鼠 | 腹腔注射 | 400mg/kg/天,连续4周 |
造模成功关键指标:血清丙氨酸氨基转移酶(ALT)、天门冬氨酸氨基转移酶(AST)水平显著升高。
药物性肝损伤模型2相关产品推荐:
分类 | 货号 | 英文名称 | 机制 |
造模药 | SJ-MX2156 | Ibuprofen | 抑制线粒体β‑氧化,与辅酶A形成硫酯,产生大量活性氧 |
SJ-MX2156A | Ibuprofen L-lysine | ||
SJ-MX2156B | Ibuprofen sodium | ||
治疗药 | SJ-BP0342 | BPC 157 | 逆转布洛芬所致肝肿大,显著降低血清AST、ALT水平 |
SJ-MN3993 | Silymarin | 抗氧化、抗凋亡、抗炎 |
参考文献:
[1]Tiwari, Shuchita, et al. Gender-Specific Changes in Energy Metabolism and Protein Degradation as Major Pathways Affected in Livers of Mice Treated with Ibuprofen.Scientific Reports, vol.10, no.1, 2020, p.3386.
[2]AlKandari, Fajer M., et al. Protective Effects of Propolis and Chitosan Nanoparticles against Ibuprofen-Induced Hepatotoxicity in Albino Rats.Diseases, vol.12, no.3, 2024, p.49.
[3]Ilic, Spomenko, et al. Ibuprofen Hepatic Encephalopathy, Hepatomegaly, Gastric Lesion and Gastric Pentadecapeptide BPC157 in Rats.European Journal of Pharmacology, vol.667, 2011, pp.322-329.
[4]Wen, Congcong, et al. Metabolism of Liver CYP450 and Ultrastructural Changes after Long-erm Administration of Aspirin and Ibuprofen.Biomedicine & Pharmacotherapy, vol.108, 2018, pp.208-215.
[5]Wen, Congcong, et al. Metabolism of Liver CYP450 and Ultrastructural Changes after Long-Term Administration of Aspirin and Ibuprofen.Biomedicine & Pharmacotherapy, vol.108, 2018, pp.208-215.
来自于公开发表的文献,仅供参考
所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类 或动物的临床诊断或治疗,非药用,非食用